Cannabigerol
CBG
The precursor molecule that most other cannabinoids are built from. Widely marketed, thinly evidenced in humans.
Evidence status
Animal and in-vitro studies only. We are not aware of adequately powered human clinical trials supporting the common consumer claims.
CBG is sometimes called the "mother cannabinoid" because CBGA, its acidic form, is the biosynthetic precursor from which THCA and CBDA are formed in the living plant. By harvest, most CBGA has been converted, so mature flower typically contains very little CBG unless the cultivar was bred for it.
Preclinical work suggests anti-inflammatory and neuroprotective activity, and there is early interest in inflammatory bowel conditions and glaucoma. None of this has been established in adequately powered human trials.
If you see CBG marketed with confident claims about focus, inflammation, or antibacterial effects, treat those as hypotheses rather than findings.
Commonly used for
- • Marketed for inflammation and focus — not clinically established
Cautions
- • Consumer claims substantially exceed the evidence.
- • Interaction profile in humans is not well characterised.